Roche Reports Phase 3 extension Data for Zanubrutinib in COVID-19

Roche today announced Phase 3 extension results for zanubrutinib in patients with COVID-19. The study demonstrated that zanubrutinib reduces hospitalization rates compared to standard of care or placebo. These results provide important insights into the treatment of COVID-19 and support the continued development of zanubrutinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.